Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2022 | The efficacy of tocilizumab in patients with advanced renal AA amyloidosis

Peter Kvacskay • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Tocilizumab

Peter Kvacskay, MD, Heidelberg University Hospital, Heidelberg, Germany, briefly discusses the efficacy of tocilizumab in patients with renal AA amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Peter Kvacskay

Unmet needs in patients with AA amyloidosis with renal involvement 3:46
Unmet needs in patients with AA amyloidosis with renal involvement
Peter Kvacskay • 6 Sep 2022
Strategies to manage renal AA amyloidosis and advances in this space 1:40
Strategies to manage renal AA amyloidosis and advances in this space
Peter Kvacskay • 6 Sep 2022

Related Videos

Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025
Ongoing research in gray zone lymphoma 1:07
Ongoing research in gray zone lymphoma
Kieron Dunleavy • 4 Sep 2025
Insights into gray zone lymphoma: a rare subtype of NHL 1:14
Insights into gray zone lymphoma: a rare subtype of NHL
Kieron Dunleavy • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals